ARWR – Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.ARWR
$36.65Name : Arrowhead Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $5,067,139,584.00
EPSttm : -1.2
Arrowhead Pharmaceuticals, Inc.
$36.65
0.30%$0.11Float Short %
9.24
Margin Of Safety %
Put/Call OI Ratio
0.22
EPS Next Q Diff
1.6
EPS Last/This Y
4.78
EPS This/Next Y
-2.81
Price
36.5
Target Price
42.36
Analyst Recom
1.71
Performance Q
93.54
Relative Volume
0.98
Beta
1.26
Ticker: ARWR
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-09-08 | ARWR | 27.18 | 0.38 | 0.56 | 37881 |
| 2025-09-09 | ARWR | 27.74 | 0.38 | 0.45 | 37441 |
| 2025-09-10 | ARWR | 28.94 | 0.38 | 0.25 | 37325 |
| 2025-09-11 | ARWR | 29.71 | 0.38 | 1.59 | 37343 |
| 2025-09-12 | ARWR | 29.72 | 0.37 | 0.24 | 38505 |
| 2025-09-15 | ARWR | 28.66 | 0.37 | 0.36 | 39250 |
| 2025-09-16 | ARWR | 29.43 | 0.37 | 0.02 | 39547 |
| 2025-09-17 | ARWR | 29.13 | 0.36931523878587 | 0.15185185185185 | 39654 |
| 2025-09-18 | ARWR | 31.54 | 0.37 | 0.12 | 39808 |
| 2025-09-22 | ARWR | 32.06 | 0.15 | 0.04 | 17499 |
| 2025-09-23 | ARWR | 32.52 | 0.15 | 0.05 | 18428 |
| 2025-09-24 | ARWR | 32.85 | 0.14 | 0.84 | 18766 |
| 2025-09-25 | ARWR | 31.66 | 0.23 | 0.78 | 19770 |
| 2025-09-26 | ARWR | 32.83 | 0.25 | 0.07 | 19978 |
| 2025-09-29 | ARWR | 33.7 | 0.25 | 0.11 | 20036 |
| 2025-09-30 | ARWR | 34.59 | 0.25 | 0.22 | 20501 |
| 2025-10-01 | ARWR | 35.02 | 0.25 | 0.15 | 20623 |
| 2025-10-02 | ARWR | 34.59 | 0.24 | 0.05 | 21457 |
| 2025-10-03 | ARWR | 36.12 | 0.24 | 0.12 | 21697 |
| 2025-10-06 | ARWR | 37.5 | 0.24 | 0.04 | 22423 |
| 2025-10-07 | ARWR | 36.54 | 0.22 | 0.57 | 24573 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-09-08 | ARWR | 27.17 | 84.5 | -81.0 | -0.13 |
| 2025-09-09 | ARWR | 27.74 | 81.1 | -97.9 | -0.18 |
| 2025-09-10 | ARWR | 28.90 | 81.1 | -102.1 | -0.18 |
| 2025-09-11 | ARWR | 29.72 | 81.1 | -99.4 | -0.18 |
| 2025-09-12 | ARWR | 29.71 | 81.1 | -93.7 | -0.18 |
| 2025-09-15 | ARWR | 28.67 | 79.7 | -86.9 | -0.22 |
| 2025-09-16 | ARWR | 29.42 | 79.7 | -98.9 | -0.22 |
| 2025-09-17 | ARWR | 29.12 | 79.7 | -91.8 | -0.22 |
| 2025-09-18 | ARWR | 31.53 | 76.3 | -109.9 | -0.22 |
| 2025-09-19 | ARWR | 30.69 | 76.3 | -88.6 | -0.22 |
| 2025-09-22 | ARWR | 32.05 | 76.3 | -102.4 | -0.22 |
| 2025-09-23 | ARWR | 32.51 | 76.3 | -96.6 | -0.22 |
| 2025-09-24 | ARWR | 32.84 | 76.3 | -95.8 | -0.22 |
| 2025-09-25 | ARWR | 31.66 | 76.3 | -86.9 | -0.22 |
| 2025-09-26 | ARWR | 32.80 | 76.3 | -100.7 | -0.22 |
| 2025-09-29 | ARWR | 33.79 | 76.3 | -99.6 | -0.22 |
| 2025-09-30 | ARWR | 34.53 | 76.3 | -98.0 | -0.22 |
| 2025-10-01 | ARWR | 35.03 | 76.3 | -96.8 | -0.22 |
| 2025-10-02 | ARWR | 34.58 | 76.3 | -91.5 | -0.22 |
| 2025-10-03 | ARWR | 36.12 | 76.3 | -102.1 | -0.22 |
| 2025-10-06 | ARWR | 37.51 | 76.3 | -109.8 | -0.22 |
| 2025-10-07 | ARWR | 36.50 | 72.7 | -88.7 | -0.22 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-09-08 | ARWR | -2.14 | 0.58 | 10.12 |
| 2025-09-09 | ARWR | -2.14 | 0.58 | 10.12 |
| 2025-09-10 | ARWR | -2.14 | 0.58 | 10.12 |
| 2025-09-11 | ARWR | -2.14 | 0.58 | 9.92 |
| 2025-09-12 | ARWR | -2.14 | 0.58 | 9.92 |
| 2025-09-15 | ARWR | -2.14 | 0.56 | 9.92 |
| 2025-09-16 | ARWR | -2.14 | 0.56 | 9.92 |
| 2025-09-17 | ARWR | -2.29 | 0.56 | 9.92 |
| 2025-09-18 | ARWR | -1.79 | 0.56 | 9.92 |
| 2025-09-19 | ARWR | -1.79 | 0.56 | 9.92 |
| 2025-09-22 | ARWR | -1.79 | 0.59 | 9.92 |
| 2025-09-23 | ARWR | -1.79 | 0.59 | 9.92 |
| 2025-09-24 | ARWR | -1.79 | 0.59 | 9.92 |
| 2025-09-25 | ARWR | -1.79 | 0.59 | 9.24 |
| 2025-09-26 | ARWR | -1.79 | 0.59 | 9.24 |
| 2025-09-29 | ARWR | -1.79 | 0.62 | 9.24 |
| 2025-09-30 | ARWR | -1.79 | 0.62 | 9.24 |
| 2025-10-01 | ARWR | -1.79 | 0.62 | 9.24 |
| 2025-10-02 | ARWR | -1.79 | 0.62 | 9.24 |
| 2025-10-03 | ARWR | -1.79 | 0.62 | 9.24 |
| 2025-10-06 | ARWR | -1.99 | 0.93 | 9.24 |
| 2025-10-07 | ARWR | -1.99 | 0.93 | 9.24 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.26
Avg. EPS Est. Current Quarter
-0.32
Avg. EPS Est. Next Quarter
0.34
Insider Transactions
-1.99
Institutional Transactions
0.93
Beta
1.26
Average Sales Estimate Current Quarter
154
Average Sales Estimate Next Quarter
244
Fair Value
Quality Score
31
Growth Score
37
Sentiment Score
85
Actual DrawDown %
61
Max Drawdown 5-Year %
-89
Target Price
42.36
P/E
Forward P/E
PEG
P/S
8.82
P/B
9.66
P/Free Cash Flow
EPS
-1.26
Average EPS Est. Cur. Y
-0.22
EPS Next Y. (Est.)
-3.03
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-25.9
Relative Volume
0.98
Return on Equity vs Sector %
-53.6
Return on Equity vs Industry %
-39.9
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.08
EBIT Estimation
-88.7
Arrowhead Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 609
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.
stock quote shares ARWR – Arrowhead Pharmaceuticals, Inc. Stock Price stock today
news today ARWR – Arrowhead Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ARWR – Arrowhead Pharmaceuticals, Inc. yahoo finance google finance
stock history ARWR – Arrowhead Pharmaceuticals, Inc. invest stock market
stock prices ARWR premarket after hours
ticker ARWR fair value insiders trading